PRESS RELEASE

Dornier MedTech Announces Poster Presentation At The Asia Pacific Urofair 2018 In Singapore

Singapore, 12 July 2018 – Dornier MedTech, a global leader in innovative kidney stone management, today announced that it will be presenting at the annual Asia Pacific Urofair 2018 taking place at Grand Hyatt Singapore on 12 – 14 July 2018.

Presented by Dr Geert G. Tailly, member of European Association of Urology, American Urological Association and Fellow of the European Board of Urology, the poster, titled *Optical Coupling Control significantly improves outcome of ESWL*, underscores the importance and benefits of optical coupling control in maximising outcomes for Extracorporeal Shockwave Lithotripsy (ESWL) treatment.

ESWL is a non-invasive treatment for urological stones and is considered the standard of care. Air bubbles are common occurrence during treatment in the coupling area, where therapy head of ESWL device and patient meet, which impact shockwave energy transfer, decreasing stone fragmentation efficiency up to 40%[1]. Optical coupling control enhances ESWL treatment and outcomes by affixing a video camera in the device head, enabling urologists to visually monitor the removal of air bubbles, which are otherwise not visible. In a study conducted by Dr Tailly comparing a group of 198 patients that received active coupling against 275 patients who received blind coupling, it has been shown that optical coupling control increases penetration of energy, significantly reducing the required number of shockwaves by 25.4% and energy levels by 23.1% for renal stones; 25.5% and 22.5% for ureteral stones[1]. Consequently, these mean more effective procedures for patients[1].

Dornier MedTech is the first and only medical device company to integrate an optical coupling control feature in its lithotripter devices, including its market leading product Dornier Delta® III. Dornier Delta III received US FDA approval in 2017, and registration for the product is underway in other markets globally.

Abel Ang, President and CEO of Dornier MedTech, said: "About one in 10 people worldwide suffer from kidney stones at some point in their lives[2]. It is also the urological condition that has the highest healthcare burden[3]. As a pioneer and market leader in non-

---

[1] Tailly, G & Tailly-Cusse MM. Optical coupling control: an important step toward better shockwave lithotripsy. J Endourol. 2014 Nov;28(11):1368-73. doi: 10.1089/end.2014.0338. Epub 2014 Aug 12.

[2] Mayo Clinic

[3] Prevalence of Kidney Stones in the United States Charles D. Scales Jr.etc., American Urological Association, Urology Care Foundation

invasive ESWL, we are committed to continuously innovate and advance medical technology that makes a difference in the treatment landscape of urological stones. We make significant investments in our clinical and research programmes, build on our clinical leadership and develop relevant and innovative products that enable urologists worldwide to deliver better outcomes for patients."

Details of the poster presentation are below:
Title: Optical coupling control significantly improves outcome of ESWL
Date/Time: 14 July 2018, 0830 – 1000
Location: Grand Hyatt, Residence 2

Ends

Media Contact:

Emma Thompson/ Stephanie Tan
+65 6340 7287
accuron@spurwingcomms.com

About Dornier MedTech
Dornier MedTech is headquartered in Munich, Germany, and is a full subsidiary of Accuron MedTech. Dornier is a medical device company focused on providing leading technology and improving life by delivering scientifically superior products and solutions to physicians, healthcare providers and research groups involved in urological care. As pioneers of the lithotripsy and a variety of surgical lasers, Dornier's 40 years of innovation and service has made it one of the most trusted MedTech companies in the industry.